IP Library Granted Patent US 10,058,276
Granted Patent B2
US 10,058,276 · App. 15/153,813 · Granted Aug 28, 2018

MEMS affinity sensor for continuous monitoring of analytes

Inventors: Qiao Lin (New York, NY); Xian Huang (New York, NY)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
A61B5/1473A61B5/0015A61B5/14532B01L3/502753G01N27/327G01N33/5438G01N33/66A61B2562/028B01L2200/10B01L2200/147B01L2200/148B01L2300/023B01L2300/0645B01L2300/0663B01L2300/0874B01L2300/1822B01L2400/043B01L2400/0433G01N27/226
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,058,276
App. No.
15/153,813
Granted
Aug 28, 2018
Kind
B2
Abstract

Techniques for monitoring a target analyte in a sample using a polymer capable of binding to the target analyte are disclosed. An implantable monitor useful for the disclosed techniques includes a microdevice coupled with a wireless interface. The wireless interface can comprise a capacitance digital converter coupled with the microdevice and can be adapted to produce a digital signal representing a measurement of the target analyte. A microcontroller can be coupled with the capacitance digital converter and a transponder can be coupled with the microcontroller to transmit the digital signal received from the capacitance digital converter to an external reader.

Claims (18)

1. An implantable monitor for monitoring a target analyte in interstitial fluid of a subject, comprising a microdevice coupled with a wireless interface;

wherein the microdevice comprises:

a semi-permeable membrane structure;

a substrate; and

a first microchamber and a second microchamber, each formed between the semi-permeable membrane structure and the substrate, each of the first and second microchambers comprising a suspended element positioned to be spaced apart from the substrate;

wherein the suspended element in each of the first and second microchambers comprises a perforated top electrode and the substrate comprises a bottom electrode;

wherein the first microchamber is adapted to receive a solution including a polymer capable of binding the target analyte;

wherein the second microchamber is adapted to receive a reference solution for screening effects not caused by the target analyte;

wherein perforations in the top electrode in the first microchamber are configured to allow the solution to fill a gap between the top electrode in the first microchamber and the bottom electrode;

wherein perforations in the top electrode in the second microchamber are configured to allow the reference solution to fill a gap between the top electrode in the second microchamber and the bottom electrode;

wherein the semi-permeable membrane structure is permeable to the target analyte and impermeable to the polymer, thereby when the sample is placed in contact with the semi-permeable membrane structure, the target analyte, if present in the sample, permeates the semi-permeable membrane structure and enters the first microchamber and the second microchamber, respectively, and the polymer is prevented from escaping from the first microchamber through the semi-permeable membrane structure.

2. The implantable monitor of claim 1 , wherein the target analyte is glucose.

3. The implantable monitor of claim 1 , wherein the wireless interface comprises:

a capacitance digital converter coupled with the microdevice and adapted to produce a digital signal representing a measurement of the target analyte in the interstitial fluid of the subject;

a microcontroller coupled with the capacitance digital converter; and

a transponder coupled with the microcontroller to transmit the digital signal received from the capacitance digital converter to an external reader.

4. The implantable monitor of claim 3 , wherein the capacitance digital converter is a Σ-Δ capacitance digital converter.

5. The implantable monitor of claim 3 , wherein the transponder is adapted to modulate the digital signal by using a first carry frequency and a second carry frequency to respectively represent 1 and 0.

Assignments (1)
CONFIRMATORY LICENSE Recorded Aug 14, 2016
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039673/0050 →
Continuity (7)
Division 14160092 · Jan 21, 2014
Continuation PCTUS2012048819 · Jul 30, 2012
Provisional Application 61513335 · Jul 29, 2011
Provisional Application 61538732 · Sep 23, 2011
Provisional Application 61542113 · Sep 30, 2011
Provisional Application 61542139 · Sep 30, 2011
Related Publication 20160249837A1 · Sep 1, 2016